ArticleEMBO molecular medicine2013
Strategy for the creation of clinical grade hESC line banks that HLA-match a target population.
Article in EMBO molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Addressing the challenges of immunogenicity, heterogeneity and tumorigenicity in the clinical translation of human embryonic stem cells.Stem cell research & therapy · 2025Review
- Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease.Translational neurodegeneration · 2024Review
- Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives.Bioengineering (Basel, Switzerland) · 2022Review
- Review
- Review
- Immunologic Rejection of Transplanted Retinal Pigmented Epithelium: Mechanisms and Strategies for Prevention.Frontiers in immunology · 2021Review
- GMP-grade neural progenitor derivation and differentiation from clinical-grade human embryonic stem cells.Stem cell research & therapy · 2020Article
- Human iPSC banking: barriers and opportunities.Journal of biomedical science · 2019Review
- Review
- Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.Progress in neurobiology · 2018Review
- Biomanufacturing for clinically advanced cell therapies.Nature biomedical engineering · 2018Review
- Induced pluripotent stem cell technology: a decade of progress.Nature reviews. Drug discovery · 2017Review
- Techniques of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derivation.Archivum immunologiae et therapiae experimentalis · 2016Review
- Generation of KCL028 research grade human embryonic stem cell line carrying a mutation in the HTT gene.Stem cell research · 2016Article
- Generation of KCL024 research grade human embryonic stem cell line carrying a mutation in NF1 gene.Stem cell research · 2016Article
- Generation of KCL025 research grade human embryonic stem cell line carrying a mutation in NF1 gene.Stem cell research · 2016Article
- Generation of KCL027 research grade human embryonic stem cell line carrying a mutation in the HTT gene.Stem cell research · 2016Article
- Generation of KCL033 clinical grade human embryonic stem cell line.Stem cell research · 2016Article
- Generation of KCL036 research grade human embryonic stem cell line carrying a mutation in the HTT gene.Stem cell research · 2016Article
- Generation of KCL037 clinical grade human embryonic stem cell line.Stem cell research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Here, we describe a pre-derivation embryo haplotyping strategy that we developed in order to maximize the efficiency and minimize the costs of establishing banks of clinical grade hESC lines in which human leukocyte antigen (HLA) haplotypes match a significant proportion of the population. Using whole genome amplification followed by medium resolution HLA typing using PCR amplification with sequence-specific primers (PCR-SSP), we have typed the parents, embryos and hESC lines from three families as well as our eight clinical grade hESC lines and shown that this technical approach is rapid, reliable and accurate. By employing this pre-derivation strategy where, based on HLA match, embryos are selected for a GMP route on day 3-4 of development, we would have drastically reduced our cGMP laboratory running costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.